Galapagos NV (NASDAQ:GLPG) Given Average Rating of “Strong Sell” by Analysts

Shares of Galapagos NV (NASDAQ:GLPG) have earned an average recommendation of “Strong Sell” from the nine brokerages that are covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a sell rating and four have issued a hold rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $26.75.

Several analysts have issued reports on the stock. TD Cowen downgraded shares of Galapagos from a “strong-buy” rating to a “strong sell” rating in a research report on Thursday, January 9th. Morgan Stanley downgraded shares of Galapagos from an “equal weight” rating to an “underweight” rating and dropped their price target for the stock from $31.00 to $22.00 in a research note on Friday, February 14th. Barclays reissued an “underweight” rating on shares of Galapagos in a research report on Thursday, January 23rd. Finally, Kepler Capital Markets lowered Galapagos from a “hold” rating to a “reduce” rating in a research report on Wednesday, November 20th.

Hedge Funds Weigh In On Galapagos

Several large investors have recently modified their holdings of the stock. Gilead Sciences Inc. bought a new stake in Galapagos in the fourth quarter valued at about $461,727,000. Tang Capital Management LLC grew its position in shares of Galapagos by 208.7% in the 4th quarter. Tang Capital Management LLC now owns 2,161,200 shares of the biotechnology company’s stock worth $59,433,000 after acquiring an additional 1,461,200 shares in the last quarter. Deep Track Capital LP acquired a new position in shares of Galapagos in the 4th quarter worth approximately $21,471,000. Finepoint Capital LP increased its holdings in shares of Galapagos by 21.0% in the 4th quarter. Finepoint Capital LP now owns 674,762 shares of the biotechnology company’s stock valued at $18,556,000 after acquiring an additional 117,000 shares during the last quarter. Finally, Hudson Bay Capital Management LP raised its position in shares of Galapagos by 8.7% during the 4th quarter. Hudson Bay Capital Management LP now owns 554,300 shares of the biotechnology company’s stock valued at $15,243,000 after acquiring an additional 44,300 shares in the last quarter. Institutional investors own 32.46% of the company’s stock.

Galapagos Stock Down 0.3 %

Shares of NASDAQ GLPG opened at $25.99 on Tuesday. Galapagos has a 1-year low of $22.36 and a 1-year high of $35.18. The business has a 50-day moving average of $25.38 and a 200-day moving average of $27.13.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.